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First-in-human study of the PARP/tankyrase inhibitor E7449
in patients with advanced solid tumours and evaluation
of a novel drug-response predictor
Ruth Plummer1, Divyanshu Dua2, Nicola Cresti3, Yvette Drew1, Peter Stephens4, Marie Foegh5, Steen Knudsen6, Pallavi Sachdev7,
Bipin M. Mistry7, Vaishali Dixit8, Sharon McGonigle8, Nancy Hall7, Mark Matijevic8, Shannon McGrath8 and Debashis Sarker9
BACKGROUND: This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel
PARP 1/2 and tankyrase 1/2 inhibitor.
METHODS: E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50–800-mg doses).
Archival tumour samples from consenting patients were evaluated for the expression of 414 genes in a biomarker panel (2X-121
drug-response predictor [DRP]) found to be predictive of the response to E7449 in cell lines.
RESULTS: Forty-one patients were enrolled (13 pancreatic, 5 ovarian, 4 each with breast, lung or colorectal cancer and 11 with
other tumour types). The most common grade ≥3 treatment-related adverse event was fatigue (n= 7, 17.1%). Five patients
experienced a dose-limiting toxicity (fatigue, n= 4, 800 mg; anaphylaxis, n= 1, 600 mg) for an MTD of 600mg. E7449 exhibited
antitumour activity in solid tumours, including 2 partial responses (PRs), and stable disease (SD) in 13 patients, which was durable
(>23 weeks) for 8 patients. In 13 patients, the 2X-121 DRP identified those achieving PR and durable SD. E7449 showed good
tolerability, promising antitumour activity and significant concentration-dependent PARP inhibition following 50–800-mg oral
dosing.
CONCLUSION: The results support further clinical investigation of E7449 and its associated biomarker 2X-121 DRP.
CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov code: NCT01618136.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0916-5
BACKGROUND
Polyadenosine diphosphate (ADP)-ribose polymerases (PARPs) are
a family of highly conserved enzymes involved in a variety of
important cellular processes, including DNA damage repair.1–3 Two
PARP family members (PARP1 and PARP2) are nuclear enzymes that,
upon activation in response to DNA strand breaks, synthesise
and transfer long branches of poly (ADP ribose) (PAR) onto
DNA-associated proteins via poly(ADP ribosyl)ation.2–4 This results
in a negatively charged environment, which facilitates recruitment
of repair machinery and accelerates DNA damage repair.4,5 Because
many anticancer therapies act by inducing DNA damage in tumour
cells, investigating the therapeutic potential of PARP inhibitors has
generated considerable interest.6,7
PARP inhibitors exert cytotoxic effects through the inhibition of
the catalytic activity of PARP1/PARP2 by trapping PARP–DNA
complexes, thereby preventing DNA replication and transcription.8
Potent and specific inhibitors of PARP have been shown to
sensitise cancer cells to the DNA-damaging effects of cytotoxic
chemotherapy and radiotherapy.9 One of the key features of the
DNA repair pathway is redundancy or the capacity for alternative
proteins or molecular pathways to compensate for specific repair
deficiencies. In this pathway, there is increasing interest in the
genetic principle of “synthetic lethality,” whereby deficiency of a
sole DNA repair component renders tumour cells highly sensitive
to specific inhibition of a redundant pathway that would
otherwise be nonessential.9 PARP inhibitors have demonstrated
activity as single agents in tumours deficient in DNA repair (i.e.,
BRCA-deficient cancers), and have increased the cytotoxic effects
of certain chemotherapies when administered in combination
regimens.9 Three PARP inhibitors (olaparib, niraparib and
rucaparib) are approved for the treatment of women with
recurrent advanced ovarian cancer and deleterious germline or
somatic BRCA mutations.10–15 The US Food and Drug Administra-
tion approved olaparib in the first-line maintenance setting for
patients with BRCA-mutated advanced ovarian cancer following
the significant benefit in progression-free survival seen in
the randomised, placebo-controlled, phase 3 SOLO1 trial.10,16
The PARP inhibitors olaparib and niraparib are also indicated for
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the maintenance treatment of women with platinum-sensitive,
recurrent ovarian, fallopian tube or primary peritoneal cancer;
niraparib can be used regardless of BRCA-mutation status, whereas
olaparib is indicated for patients with BRCA mutations.10,14–16
E7449 (also known as 2X-121, herein referred to as E7449) is an
orally bioavailable, small-molecule inhibitor of the enzymatic
activity of PARP1 and PARP2 (inhibitory concentration at half-
maximal effect [IC50] of 1.0 and 1.2 nmol/L, respectively), which
traps PARP1 on DNA via dose-dependent binding to chromatin.17
E7449 also inhibits tankyrase 1 and 2, which are important
regulators of the canonical Wnt/β-catenin signalling pathway
involved in promoting tumorigenesis. In a Wnt1 preclinical model,
synergistic antitumour effects were observed when E7449 was used
in combination with the mitogen-activated protein kinase
kinase inhibitor E6210.17 In addition, E7449-mediated tankyrase
inhibition results in a significant increase in axin2 levels, and a
concomitant reduction in active and total β-catenin in human colon
cancer SW480 cells.17 E7449 demonstrated single-agent antitumour
activity in several BRCA-deficient xenograft models, as well as
potentiation of the efficacy of radiotherapy and chemotherapy in
both in vitro and in vivo models, respectively.17,18 In this first-in-
human study, we report the results of an open-label, multicentre,
phase 1 trial of single-agent E7449 in patients with advanced
malignancies. In addition, we report a novel tumour-agnostic
molecular biomarker, 2X-121 drug-response predictor [DRP], devel-
oped and tested post study, to identify patients as responders or
non-responders to therapy.
METHODS
Study design, treatment schedule and assessments
This was an open-label, multicentre, phase 1 study of single-agent
E7449 (ClinicalTrials.gov: NCT01618136). The primary endpoint
was to determine the maximum-tolerated dose (MTD) of E7449.
Secondary endpoints included assessments of safety and tolerability,
pharmacokinetic (PK) profile (including the effect of a high-fat meal
on E7449 bioavailability), pharmacodynamic (PD) effects (including
inhibition of PARP in peripheral blood mononuclear cells [PBMCs]
and effect on DNA damage), PK/PD relationships, serum biomarker
analysis and preliminary antitumour activity. The study was
conducted in full accordance with the principles of the World
Medical Association Declaration of Helsinki, the International
Conference on Harmonisation and all applicable local guidelines
and regulations on good clinical practice. All patients provided
written informed consent.
The study included a 3+ 3 dose-escalation phase in which
sequential cohorts of 3–6 patients were administered increasing oral
doses of E7449 (starting at 50mg), administered once daily in
28-day cycles. To further assess the safety and tolerability of E7499 at
the MTD, and to determine the recommended phase 2 dose, an
expansion cohort of 9–12 additional response-evaluable patients
was planned. Patients received study drug until disease progression,
development of unacceptable toxicity or withdrawal of consent.
The MTD was defined as the highest dose of E7449 at which
≤1 of 6 patients demonstrated a dose-limiting toxicity (DLT).
DLTs were assessed according to Common Terminology Criteria
for Adverse Events, version 4.03, and were defined as any grade 3
or worse haematologic or nonhaematologic toxicity occurring
during cycle 1 of the dose-escalation phase, and considered
related to E7449 by the investigator. DLTs included any grade 4
neutropenia occurring for ≥7 days or grade 3 neutropenia with
fever (>38.5 °C in axilla), grade 4 or grade 3 thrombocytopenia
with bleeding or lasting >7 days, grade 3 fatigue or a 2-point
decline in Eastern Cooperative Oncology Group (ECOG) perfor-
mance status persisting for over 7 days, persistent grade 3 or 4
nausea, vomiting or diarrhoea, despite maximal medical therapy,
grade 3 or worse nonhaematologic laboratory abnormalities
requiring hospitalisation and E7449-related adverse events (AEs)
occurring during cycle 1, resulting in the administration of <75%
of the planned E7449 dosage.
The effect of food on E7449 exposure was evaluated in cycle 1
for patients included in the expansion cohort. These patients
fasted overnight on day 7, after which, they were randomised to
receive E7449 with or without a high-fat breakfast. Fed patients
were administered E7449 immediately after consuming a meal.
Patients were then crossed over to the alternate food regimen on
day 15.
Patient eligibility
Eligible patients were ≥18 years of age with histologic and/or
cytologic confirmation of advanced or metastatic solid tumours or
B-cell lymphomas progressing after treatment with approved
therapies, or for which no standard therapies exist. Patients could
have measurable or non-measurable disease by Response Evalua-
tion Criteria in Solid Tumors, version 1.1, but only patients with
measurable disease were permitted to enter the extension phase of
the study. All eligible patients had adequate cardiac, bone marrow,
renal and liver functions, a life expectancy of ≥3 months, an ECOG
performance status of 0–2 and a left ventricular ejection fraction of
>50%. Patients with brain metastases were eligible if they had
undergone complete surgical excision or stereotactic radiosurgery or
radiotherapy, and had no radiographic evidence of brain disease
recurrence/progression, were asymptomatic and had discontinued
corticosteroid treatment ≥30 days prior to dosing.
Key exclusion criteria included prior exposure to E7449,
leptomeningeal or brain metastases (except for that as mentioned
in the inclusion criteria), use of strong-cytochrome P450 inhibitors
or inducers, any major surgery or anticancer treatment ≤4 weeks
prior to dosing, active infection requiring systemic therapy,
prolongation of heart rate-corrected QT interval to >480 ms when
electrolyte balance was normal or had any uncontrolled endocrine
disease necessitating relevant changes in medication within the
last month or hospital admission within the previous 3 months.
Safety
Safety was measured by monitoring and recording all AEs,
including all Common Terminology Criteria for Adverse Events
grades, and serious AEs (SAEs), clinical laboratory test results, vital
sign measurements and electrocardiogram and physical examina-
tion findings.
Pharmacokinetic and pharmacodynamic assessments
For the dose-escalation cohorts, blood samples for pharmacoki-
netic analyses were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 and
48 h after a single dose of E7449 administered on day −2, and
again at the same time points at steady state on day 15 of cycle 1
(excluding the 48-h sample). Blood samples were also collected
immediately before the dose on day 7 of cycle 1, days 1 and 15 of
cycle 2 and on day 1 of cycle 3, and beyond. All urine produced
during the time intervals pre-dose, 0–2 h, 2–4 h, 4–10 h and 10–24
h following the single dose on day –2, and after multiple doses on
cycle 1, day 15, was collected.
Validated liquid chromatography coupled with tandem mass
spectrometry methods was used to determine human plasma
and urine concentrations of E7449 (XenoBiotic Laboratories Inc.,
[WuXi AppTec], Plainsboro, NJ, USA). PK parameters were
calculated from the E7449 plasma concentration–time profiles
and urine excretion data using noncompartmental methods with
the Phoenix WinNonlin version 6.2.
For the dose-escalation phase of the study, blood samples for
pharmacodynamic analyses were collected at 0, 2, 4, 8 and 24 h
after single-dose administration of E7449 on day –2 and cycle 1,
day 15, and at 0 h and 4 h post dose on cycle 1, day 1 and cycle 1,
day 7. Inhibition of PARP activity was measured by quantifying
PAR in PBMCs using an enzyme-linked immunosorbent assay
(HT PARP in vivo Pharmacodynamic Assay II kit). PAR levels in
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PBMCs and the percentage change from baseline were sum-
marised by dose and nominal sampling time point.
For the food-effect expansion cohort, blood samples for the
pharmacokinetic analyses were collected prior to the E7449 dose
and then 1, 2, 3, 4, 8, 12 and 24 h after E7449 dosing on days 7 and
15 of cycle 1, when E7449 was at steady state.
Pharmacokinetic/pharmacodynamic modelling
The E7449 plasma concentration-versus-time and PAR inhibition
data in PBMCs were subjected to PK/PD modelling using a 2-stage
approach. In the first stage, the mean plasma concentration-
versus-time curves of E7449 from all doses were simultaneously
fitted to a 2-compartment pharmacokinetic model with first-order
absorption and -elimination from the central compartment. In the
second stage, the final parameters from the pharmacokinetic
model were fixed for sequential PK/PD modelling.
The PD measurement utilised in the PK/PD model was the
percentage inhibition of the formation of PAR, a marker for PARP
activity,19 which was calculated as % inhibition= (Response/
Baseline) × 100, where baseline was defined as the PAR response
at time 0 on day –2. The percent change in PAR from baseline (%
PAR) over time, as a function of E7449 plasma concentrations, was
fitted to a sigmoidal inhibitory indirect-response PK/PD model,
where E7449 inhibited the rate of formation (kin) of PAR.
20
The PK/PD model equation is shown below:
d %PARð Þ
dt
¼ kin  Imax  C
gam
ICgam50 þ Cgam
 
 kout  PAR
where C is the concentration of E7449 in the central compartment,
Imax is the maximal inhibitory effect (percent inhibition from
baseline), which was assumed to be 100%, IC50 is the E7449
concentration [ng/mL] at half-maximal effect and gam is the
sigmoidicity factor (Hill coefficient).
The model parameters from the PK/PD analysis were then used
to simulate the expected PAR responses of additional dosing
regimens of E7449. All PK/PD modelling and subsequent response
simulations were performed using Phoenix WinNonlin®, version 7.
Efficacy
Tumour assessments (computed tomography, magnetic resonance
imaging, photographs and bone scans, as suitable for tumour type),
based on Response Evaluation Criteria in Solid Tumors version 1.1,
were performed at screening and subsequently every 8 weeks until
disease progression. Investigator assessments of complete or partial
response were confirmed ≥4 weeks after initial assessment.
Serum biomarker analysis
To investigate the correlation of biomarkers and the biological
activity of single-agent E7449, blood samples were obtained from
27 patients in the dose-escalation cohort at specified time points,
processed for serum, aliquoted and stored frozen. Two pre-dose,
multiple post-dose and off-treatment time points were included.
Serum samples were tested for concentrations of soluble vascular
endothelial growth factor receptor (VEGFR)2, VEGFR3 and soluble
interleukin-2 receptor α (sIL-2Rα/CD25), using the bead-based
Human Soluble Cytokine Receptor Panel assay kit. The two
baseline samples (days −3 and −2 prior to dosing) were averaged,
and the mean was used to calculate percent change at each of the
post-dosing time points.
Tumour biomarker analysis
Seventy-four cell lines were treated with E7449, and the IC50 was
calculated after 8 days of treatment (Supplementary Table 1).
Matching baseline transcriptome and growth inhibition data were
available for 61 of the 74 cell lines, and were used to develop a DRP
as previously described.21,22 Briefly, IC50 values in the 61 cell lines
were correlated to gene-expression levels in the same cell lines;
172 genes with a Pearson correlation above 0.25 were retained as
potential markers of sensitivity, while 242 genes with a Pearson
correlation below −0.25 were retained as potential markers of
resistance. The 414 genes were searched in PubMed for known
associations to DNA damage response or Wnt/β-catenin pathways.
The 111 pathway-associated genes are shown in Supplementary
Table 2. Archival biopsies, in the form of formalin-fixed paraffin-
embedded blocks and slides, were obtained from patients in the
trial. Only those samples that yielded RNA of sufficient quantity and
quality were evaluated for gene expression. The expression of the
414 genes in the 2X-121 DRP was analysed via a custom Affymetrix
U133_Plus2 microarray according to the manufacturer’s instructions.
The 2X-121 DRP was applied in a blinded manner following a
prespecified analysis plan. The difference between the means of the
genes that were positively correlated and those negatively
correlated to response was used as a single prediction score for
each patient, after normalisation to a range of 0–100.
Statistical analysis
As a first-in-human phase 1 clinical trial, no formal sample-size
calculation or hypothesis testing was undertaken. Analysis of
biomarker predictions was performed using a 1-sided Pearson
correlation test and a 1-sided log-rank test for time-to-event data
according to a prespecified analysis plan.
RESULTS
Study population
The study was conducted between January 31, 2012 and July 14,
2015, and enrolled 41 patients from 2 sites in the United Kingdom.
All enrolled patients received 1 of 6 dose levels (50mg, 100mg, 200
mg, 400mg, 600mg and 800mg) of single-agent E7449 in the dose-
escalation phase of the study. Of the 33 patients who completed the
first cycle of treatment, 32 patients continued to receive the study
drug, and were included in the extension phase of the study. Most
patients completed the dose-escalation and extension phases of the
study (80% [33/41] and 84% [27/32], respectively); 21 patients
received the MTD (600mg), 13 of whom then enrolled as part of the
food-effect cohort in the expansion phase.
Demographic and baseline characteristics of the patients are
summarised in Table 1. Most patients had an ECOG performance
status of 0 (22.0%) or 1 (58.5%); 78% had received ≥2 prior
anticancer therapies. The most common primary tumour sites were
pancreas (n= 13), ovary (n= 5), breast (n= 4), lung (n= 4), color-
ectal (n= 4) and pleura (n= 3). Although BRCA testing was not
mandated by the protocol, a total of 6 patients had germline BRCA
mutations confirmed by the investigator (ovarian cancer, n= 3,
breast cancer, n= 2 and pancreatic cancer, n= 1).
Safety
DLTs were observed in 5 of the 25 evaluable patients (Table 2).
One DLT occurred in the 600-mg dose cohort (grade 3
anaphylactic reaction) and 4 in the 800-mg dose cohort (fatigue
[grade 3, n= 1; grade 2, n= 3], leading to administration of <75%
of the planned E7449 dose). An E7449 dose of 600 mg,
administered orally and once daily, was defined as the MTD,
and is the recommended phase 2 dose.
Across dose cohorts, the mean number of E7449 treatment
cycles was 3.8 (median, 2; range, <1–14), and the median duration
of E7449 treatment was 57 days (range, 1–392). Grade 3 AEs were
reported in 27 patients (65.9%), with fatigue being the most
common (17.1% [7/41]). One grade 4 AE (hypokalaemia, not
treatment-related) was observed in 1 patient in the 200-mg dose
cohort. No grade 5 AEs were reported. Nonfatal SAEs were
reported in 58.5% (24/41) of patients.
Thirty-nine patients (95.1%) in the dose-escalation cohort had
treatment-related AEs, with the most common being fatigue (63%),
chromaturia (49%), nausea (34%), diarrhoea (29%), maculopapular
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rash (27%), photosensitivity reaction (24%) and decreased appetite
(24%) (Table 3). Treatment-related grade 3 fatigue occurred in
4 patients (600mg, n= 2; 800mg, n= 2). E7449 treatment
was discontinued in 17% (7/41) of patients due to AEs (50mg,
n= 1; 600mg, n= 4; 800mg, n= 2). Fatigue (n= 3) was the most
common AE leading to treatment discontinuation.
Treatment-emergent AEs associated with skin rash events
were reported by 41.5% (17/41) of patients who received ≥100-
mg doses of E7449 (47.6% in the 600-mg dose cohort and 66.7%
in the 800-mg dose cohort). Preferred AE terms associated with
rash included maculopapular rash (n= 11), erythematous rash
(n= 4), acneiform dermatitis (n= 2), blister (n= 1) and rash
(n= 1). None of the reported skin rash events were considered
serious, and all were of grade 1 or 2 severity, with the exception
of one grade 3 erythematous rash event in the 600-mg dose
cohort. Because E7449 treatment increased photosensitivity,
patients were advised to avoid sun exposure, use sunscreen,
wear protective clothing and to consult a dermatologist in the
event of any rash occurring. In addition, treatment-emergent
chromaturia was experienced by 51.2% (21/41) of patients
(50.0% in the 400-mg, 66.7% in the 600-mg and 83.3% in the
800-mg dose cohorts), and all events of chromaturia were
grade 1.
Pharmacokinetics
E7449 PK parameters following a single dose and at steady state
are summarised in Table 4. E7449 was rapidly absorbed with the
tmax at steady state ranging from 0.5 to 4 h across dose cohorts.
The elimination half-life, t1/2, was approximately 8 h, and the
accumulation ratio, Rac, was less than 1.2-fold across the range of
doses, indicative of no accumulation of E7449 at steady state. Less
than 1.5% of the drug dose was excreted unchanged in urine.
E7449 exposure (Cmax and AUC) following oral administration was
increased roughly proportionally from 50mg to 800 mg following
single or multiple doses. At the 600-mg dose, consumption of a
high-fat meal delayed E7449 absorption, as indicated by a shift in
tmax by 2 h, and a reduction in Cmax by 60%. However, overall
exposure, as measured by AUC (0–24 h or 0-t) increased to ~10%
(Supplementary Table 3).
Table 1. Patient baseline characteristics (safety analysis set).
Characteristic Patients, n (%) (N= 41)
Median age, years (range) 65.0 (24, 76)
Sex
Male 22 (53.7)
Female 19 (46.3)
Race
White 40 (97.6)
Asian 1 (2.4)
Eastern Cooperative Oncology Group performance status
0 9 (22.0)
1 24 (58.5)
2 1 (2.4)
Missing 7 (17.1)
Number of prior anticancer therapies
0 1 (2.4)
1 7 (17.1)
2 14 (34.1)
3 7 (17.1)
4 5 (12.2)
5 5 (12.2)
6 1 (2.4)
Location of primary tumour
Adrenal glands 1 (2.4)
Breasta 4 (9.8)
Gallbladder and extrahepatic bile ducts 1 (2.4)
Kidney 1 (2.4)
Large intestine (excluding the appendix) 4 (9.8)
Lung and bronchus 4 (9.8)
Oesophagus 1 (2.4)
Ovaryb 5 (12.2)
Pancreasc 13 (31.7)
Pleura 3 (7.3)
Retroperitoneum and peritoneum 1 (2.4)
Skin 1 (2.4)
Small intestine 2 (4.9)
aTwo patients had BRCA mutation.
bThree patients had BRCA mutation.
cOne patient had BRCA mutation.
Table 2. Summary of exposure and dose-limiting toxicities (safety
analysis set).
E7449 dose cohort
(n)
Median
number of
cycles
received
(range)
Evaluable
patients, n
Patients with
dose-limiting
toxicity, n (%)
Dose-limiting-toxicity
description
50mg (n= 3) 6 (1, 8) 3 0 —
100mg (n= 3) 2 (2, 14) 3 0 —
200mg (n= 4) 3 (1, 4) 4 0 —
400mg (n= 4) 5 (0, 10) 3 0 —
600 mga (n= 8) 2 (0, 13) 6 1 (16.7) Grade 3 anaphylactic
reaction
800mg (n= 6) 2 (0, 11) 6 4 (66.7) Grade 3 fatigue
(n= 1)
Grade 2 fatigue
(n= 3)
aSelected as the maximum-tolerated dose.
Table 3. Most common treatment-related adverse events occurring in
>5% of patients overall (any Common Terminology Criteria for Adverse
Events grade; safety analysis set).
Preferred term, %a E7449 dose cohort, mg
50
(n= 3)
100
(n= 3)
200
(n= 4)
400
(n= 4)
600b
(n= 21)
800
(n= 6)
Total
(N= 41)
Fatigue 33.3 66.7 0 75.0 66.7 100.0 63.4
Chromaturia 0 0 0 50.0 66.7 66.7 48.8
Nausea 33.3 33.3 50.0 25.0 33.3 33.3 34.1
Diarrhoea 33.3 33.3 0 50.0 23.8 50.0 29.3
Maculopapular rash 0 33.3 25.0 25.0 33.3 16.7 26.8
Decreased appetite 33.3 0 0 25.0 23.8 50.0 24.4
Photosensitivity reaction 33.3 33.3 0 25.0 23.8 33.3 24.4
Vomiting 33.3 0 25.0 0 14.3 33.3 17.1
Depression 0 33.3 25.0 50.0 4.8 16.7 14.6
Periorbital oedema 0 0 0 25.0 19.0 0 12.2
Pruritus 0 33.3 0 0 19.0 0 12.2
Skin hyperpigmentation 0 33.3 0 0 9.5 33.3 12.2
Increased blood alkaline
phosphatase
0 0 0 25.0 14.3 0 9.8
Constipation 33.3 33.3 0 0 9.5 0 9.8
Dry skin 0 33.3 0 0 4.8 33.3 9.8
Abdominal pain 0 33.3 0 25.0 0 16.7 7.3
Anaemia 33.3 0 0 0 9.5 0 7.3
Dizziness 0 0 0 0 4.8 33.3 7.3
Dysgeusia 0 0 0 0 14.3 0 7.3
Onycholysis 0 0 0 25.0 9.5 0 7.3
Erythematous rash 0 0 0 0 9.5 16.7 7.3
aAdverse events were coded using Medical Dictionary for Regulatory Activities version 17.1
and graded using Common Terminology Criteria for Adverse Events version 4.03.
bMaximum-tolerated-dose cohort, n= 8; food-effect cohort, n= 13.
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Pharmacodynamics
Dose-dependent inhibition of PARP activity, as measured by the
percentage change of PAR levels in PBMCs, was observed with
E7449 treatment. Maximal inhibition was achieved at the MTD
(600 mg once daily) (Fig. 1). At the MTD, the population mean
frequency of PARP inhibition was approximately 90% at steady
state (Fig. 1). PARP inhibition was sustained with a ≥ 70%
decrease in PAR levels at 24-h post-dose time points (cycle 1,
days 1, 7, 8 and 16 [at 0 h for each]). An increased effect of E7449
on PAR levels was observed with increased exposure to E7449
up to and including the 600-mg dose (Supplementary Fig. 1A).
PAR levels remained suppressed over the 24-h dosing interval
even though E7449 concentrations decreased rapidly (Supple-
mentary Fig. 1B). In the food-effect cohorts with (fed and unfed)
patients treated at the MTD, PARP inhibition was sustained
during treatment with E7449 up to 24 h post dose. The maximal
decrease in PAR levels occurred at 2–4 h after administration of
E7449 in the fasted cohort, and 4–8 h post treatment in the fed
cohort, with up to 90% inhibition in PAR levels from baseline
(Supplementary Fig. 2).
Pharmacokinetic/pharmacodynamic modelling
The fitted PK model curves and observed PK data for the six E7449
dose levels are shown in Supplementary Fig. 3A. The absorption
rate constant (ka) was estimated to be 0.82 h
−1 with a first-order
elimination rate constant (ke) of 0.51 h
−1. The apparent volume of
distribution for the central compartment (V/F) was estimated to be
149.7 L, and the distribution rate constants between the central
and the peripheral compartment were estimated to be 0.21 h−1
(k12) and 0.27 h
−1 (k21). The compartmental PK parameters were
estimated with reasonable confidence (% coefficient of variation
range, 10–47%) (Supplementary Table 4).
The sigmoidal indirect-response PK/PD model fits the time
course of target modulation reasonably well, with an estimated
IC50 of 0.2 µg/mL PK (Supplementary Fig. 3B). The model tended
to overpredict the percent inhibition of PAR at the lowest dose
on both day 1 and day 15; however, the PK/PD model fits
the higher-dose data reasonably well. The PD parameter
estimates and their coefficients of variance are shown in
Supplementary Table 4. The final PK/PD model was used to
simulate different E7449 dosing regimens that may show
Table 4. E7449 pharmacokinetic parameters (pharmacokinetic analysis set).
Day –2 (single dose)
Dose 50mg 100mg 200mg 400mg 600mg 800mg
n 3 3 4 4 8 6
Cmax (ng/mL) 265 (99.8) 284 (112) 996 (676) 999 (619) 2250 (1330) 4430 (2470)
tmax (h) 2.00 (0.58, 2.03) 2.05 (1.08, 3.00) 3.10 (1.03, 4.18) 2.04 (1.03, 4.05) 2.12 (0.50, 24.3) 0.79 (0.50, 2.00)
AUC(0–24) (ng·h/mL) 768 (n= 1) 879 (104) 3670 (1170) 4690 (2400) 7930 (4990) 11,300 (3230)
AUC(0-t) (ng·h/mL) 603 (213) 879 (104) 3780 (1180) 4800 (2450) 8120 (4990) 11,500 (3370)
AUC(0-inf) (ng·h/mL) 770 (n= 1) 895 (99.8) 3320 (1790) (n= 2) 4800 (3000) (n= 3) 10,700 (5040) (n= 4) 12,900 (3350) (n= 4)
t1/2 (h) 3.42 (n= 1) 6.35 (3.36) 7.08 (1.16) (n= 2) 8.62 (0.54) (n= 3) 7.17 (2.98) (n= 4) 9.45 (2.42) (n= 4)
CL/F (L/h) 64.9 (n= 1) 113 (12.9) 70.7 (38.3) (n= 2) 104 (50.1) (n= 3) 64.1 (23.8) (n= 4) 64.7 (13.4) (n= 4)
Vz/F (L) 321 (n= 1) 1070 (687) 690 (273) (n= 2) 1320 (689) (n= 3) 741 (496) (n= 4) 864 (230) (n= 4)
Ae (mg) 0.11 (0.06) (n= 2) 0.47 (n= 1) 0.70 (0.60) (n= 3) 2.77 (1.82) 2.90 (0.51) 4.00 (1.73)
fe (%) 0.22 (0.13) (n= 2) 0.47 (n= 1) 0.34 (0.29) (n= 3) 0.69 (0.45) 0.48 (0.09) 0.50 (0.22)
CLR (L/h) – (n= 0) 0.5 (n= 1) 0.2 (0.15) (n= 3) 0.6 (0.34) 5.0 (13.0) 0.4 (0.12)
Cycle 1, day 15 (multiple once-daily doses), steady state
n 3 3 3 3 6 5
Cmax (ng/mL) 264 (227) 404 (175) 1430 (1080) 1130 (1030) 2230 (1570) 4120 (2160)
tmax (h) 1.00 (0.5, 2.00) 3.00 (1.00, 4.00) 1.00 (1.00, 2.00) 4.00 (0.5, 4.00) 1.14 (0.50, 4.05) 0.50 (0.0, 1.97)
AUC(0–24) (ng·h/mL) 714 (193) 1100 (244) 3690 (2230) 4730 (2730) 7900 (4730) 12,400 (5230)
AUC(0-inf) (ng·h/mL) 634 (n= 1) 1150 (266) 2670 (1510) (n= 2) 3240 (820) (n= 2) 9660 (4550) (n= 4) 12,000 (5910) (n= 4)
t1/2 (h) 9.04 (n= 1) 8.92 (2.50) 9.19 (4.83) (n= 2) 4.16 (1.72) (n= 2) 5.05 (1.76) (n= 4) 6.44 (1.56) (n= 4)
Cav,ss (ng/mL) 29.7 (8.03) 45.8 (10.2) 154 (93.1) 197 (114) 329 (198) 516 (218)
CLss /F (L/h) 73.1 (17.1) 94.2 (22.9) 73.3 (50.4) 103 (50.5) 133 (139) 67.1 (28.2)
Rac 1.19 (n= 1) 1.19 (0.11) 1.22 (0.22) (n= 2) 1.03 (0.04) (n= 2) 1.05 (0.05) (n= 4) 1.09 (0.06) (n= 4)
Ae (mg) 0.19 (0.00) (n= 2) 0.70 (n= 1) 1.11 (0.33) 2.05 (1.09) 2.25 (1.28) 4.70 (2.91)
fe (%) 0.39 (0.01) (n= 2) 0.70 (n= 1) 0.55 (0.17) 0.51 (0.27) 0.38 (0.21) 0.68 (0.47)
CLR (L/h) 0.3 (0.01) (n= 2) 0.5 (n= 1) 0.5 (0.4) 0.4 (0.14) 0.3 (0.12) 0.5 (0.34)
Data are the mean (standard deviation) except for tmax.
For tmax, median (minimum –maximum) is shown.
Ae, amount of drug dose excreted in urine; AUC(0–24), area under the concentration–time curve from time zero (pre-dose) to 24 h post dose; AUC(0-t), area under
the concentration–time curve from time zero (pre-dose) to the time of the last quantifiable concentration; AUC(0-inf ), area under the concentration–time curve
from time zero (pre-dose) extrapolated to infinite time; Cav,ss, average steady-state concentration during multiple-dose administration; Cmax, maximum
observed concentration; CL/F, apparent total clearance following oral administration; CLss/F, apparent total clearance at steady state following oral
administration; CLR, renal clearance; fe, cumulative fraction of drug dose excreted/recovered in urine; Rac, accumulation ratio; tmax, time at which the highest
drug concentration occurs; t1/2, terminal elimination phase half-life; Vz/F, apparent volume of distribution at the terminal phase.
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sustained inhibition of PAR formation. The simulations indicate
that a twice-daily E7449 dosing regimen is needed for sustained
inhibition of the PARP enzyme. For example, simulations
showed that a E7449 200-mg twice-daily or a 300-mg twice-
daily dose showed a sustained inhibition of the target. However,
the PAR response following the same dose given once a day
(i.e., 400-mg or 600-mg once daily), returned to baseline faster
than the twice-daily regimen.
Efficacy
The objective response rate (ORR) was 4.9% (2/41) with 2 patients
with ovarian cancer (1 each in the 600-mg and 800-mg dose
cohorts) achieving a partial response. Thirteen (31.7%) of the 41
patients had the best overall response of stable disease with a
median duration of 162 days (52–262 days). Of the 35 patients who
were evaluated for the best overall response, 13 patients, including
3 patients with previously treated ovarian cancer (2 patients with
partial response and 1 patient with stable disease), had a decrease
in target lesion size (Supplementary Fig. 4). The ORR in patients
with germline-mutated BRCA was 16.7% (1/6). Of the 6 patients
with known BRCA mutations, stable disease was observed in
2 patients (pancreatic and high-grade serous ovarian tumour),
partial response in 1 patient (high-grade serous ovarian tumours)
and progressive disease in 3 patients (2 breast tumours and
1 ovarian tumour). None of the BRCA-mutated patients (n= 6) in
this study had prior treatment with a PARP inhibitor, whereas two-
thirds (4/6: ovarian, n= 3; breast, n= 1) had prior platinum
exposure—most of whom were platinum-sensitive, and one was
resistant, at the time of study enrolment (Supplementary Table 5).
Serum biomarker analysis
Assessment of serum biomarker concentrations over time demon-
strated that E7449 conferred an effect on sIL-2Rα concentrations,
although a dose-dependent relationship between sIL-2Rα was not
observed. Increased sIL-2Rα was observed from 48 h onwards and in
all dose groups, with up to 150% change above baseline recorded
(Supplementary Fig. 5A). A range of endogenous variability of
sIL-2Rα concentrations was determined using serum samples
collected within a 2-week time period from 10 healthy controls.
The endogenous fluctuation of sIL-2Rα levels was determined to
be +/−20% from baseline (Supplementary Fig. 5B). Thus, the
observed increases in sIL-2Rα of up to 150% change from baseline
appear to be E7449-dependent. No significant changes in serum
concentrations from baseline were observed for sVEGFR2 and
sVEGFR3 (data not shown).
Tumour biomarker analysis
A novel, tumour-agnostic, molecular biomarker, 2X-121 DRP, was
developed to identify responders and non-responders using 61
cell lines as previously described.21,22 In these tumour cell lines,
414 genes were found to predict response to E7449: 172 genes
were found to be positively correlated with sensitivity to E7449,
and 242 genes were negatively correlated. Among these 414
genes predictive of the response to E7449, 111 were found to be
associated in the literature with DNA damage response or Wnt/β-
catenin pathways (Supplementary Table 2). Tumour biopsies from
16 patients in the trial were analysed, and the RNA samples from
13 of these patients, which were of sufficient quantity and quality,
were evaluated for the expression of the 414 predictive genes
used in the 2X-121 DRP (via a custom Affymetrix microarray).
The 2X-121 DRP was applied to the gene-expression profiles
obtained from tumour biopsies of these 13 patients and, using a
prespecified DRP cut-off sensitivity score of 50, was used to
predict sensitivity to E7449. The resultant DRP score correctly
identified the 2 partial responders as highly sensitive (Fig. 2a).
A non-responder whose 2X-121 DRP results (a score of 93)
predicted the patient to be highly sensitive to E7449 showed
extended progression-free survival (no progression by the last
assessment at 321 days and alive at the last follow-up assessment
at 406 days). The Pearson correlation between dose-adjusted
prediction scores and changes in baseline tumour diameter was
−0.43 (P= 0.07). Based on the DRP score and the prespecified cut-
off of 50, 6 patients were predicted to be sensitive to E7449
treatment, and 7 patients were predicted to be not sensitive. The
group of patients predicted to be sensitive, compared with those
predicted to be not sensitive to E7449 treatment, did have a
longer median time to progression (296 vs. 155 days, respectively;
HR= 0.29; P= 0.06) and median overall survival (>800 days vs.
208 days, respectively; HR= 0.26; P= 0.04, Fig. 2b).
To determine whether the DRP is prognostic or predictive, we
tested it in a published dataset of triple-negative breast cancer,
which has previously been used for developing prognostic
signatures.23 The hazard ratio in event-free survival between 32
patients predicted to be E7449-sensitive and 32 patients predicted
to be E7449-resistant is 1.0, leading to the conclusion that the
signature is likely not prognostic.
DISCUSSION
This phase 1 study evaluated the MTD, safety and tolerability,
PK/PD profile and preliminary activity of single-agent E7449 in
patients with advanced solid tumours. The study met its primary
endpoint, and the MTD and recommended phase 2 dose of E7449
monotherapy was determined to be 600 mg, administered orally
once daily.
PARP inhibitors are generally well tolerated as single agents.
The most commonly reported AEs associated with the 3 approved
PARP inhibitors are fatigue, nausea and vomiting, and haemato-
logic AEs such as anaemia and thrombocytopenia.24–26 Consistent
with these class effects, the most common E7449-related AE
observed in this study was fatigue. Unexpectedly, E7449-related
AEs included maculopapular rash (33.3% at the MTD), photo-
sensitivity (23.8% at the MTD) and chromaturia (66.7% at the
MTD), which have not been reported previously in clinical trials of
other PARP inhibitors. Although rash appeared to be the result of
E7449-related phototoxicity, its incidence was minimised through
incorporation of sunlight-prevention measures. When skin rash
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appeared, it was improved with drug interruption. Chromaturia
also appeared to be an E7449-specific event, resulting from
generation of an E7449-derived metabolite that appeared green
to the eye.
E7449-related haematological toxicity was observed infre-
quently in this study. At the MTD, grade 1 thrombocytopenia
was observed in 1 patient (1/21, 5%), and anaemia (≤grade 2) was
observed in 4 patients (4/21, 19%). The mean number of cycles
was 3.8 (minimum, maximum: 0, 14), which may account for the
limited number of treatment-related anaemia events observed in
this study. As haematologic toxicity may serve as a barrier to
combination strategies with chemotherapy,24 the lack of higher-
grade haematologic toxicities with E7449 may facilitate the
evaluation of combination regimens, which may be needed to
treat advanced malignancies.
Following single or multiple doses, moderately rapid absorption
of E7449 was observed. Although food reduced the absorption
rate (as Cmax declined by 60% and tmax increased by 2 h), overall
absorption was minimally impacted with a modest 10% increase
in AUC. PARP inhibition with E7449 was dose-dependent, with
maximal inhibition of PARP activity at the E7449 MTD. In addition,
sustained inhibition of PARP activity was achieved, and maximal
inhibition of PARP activity correlated with peak plasma concen-
trations of E7449.
Veliparib and talazoparib are 2 additional oral PARP1/PARP2
inhibitors in clinical development that have demonstrated single-
agent antitumour activity in both BRCA-positive and BRCA–wild-type
tumours.27–29 In this study, E7449 monotherapy demonstrated
preliminary antitumour activity in patients with advanced solid
tumours, irrespective of BRCA status.
Compared to other licensed or investigational PARP inhibitors,
the preclinical profile of E7449 most closely resembles that
of olaparib and niraparib.17,26 Olaparib, niraparib and E7449
have all demonstrated trapping of PARP1 on DNA, resulting in
augmented cytotoxicity.17,30
Using an indirect-response model, the relationship between
E7449 plasma concentration and PARP inhibition was established.
The PK/PD relationship provided a useful tool to evaluate
additional dosing regimens, including the opportunity to define
the optimal dosing strategy for E7449. PK/PD simulations suggest
that twice-daily dosing may provide an improved profile of
sustained PARP inhibition over 24 h, especially at lower doses.
Twice-daily dosing regimens have been adopted for other PARP
inhibitors, including olaparib10 and veliparib.27 Dosing schedules
for these particular PARP inhibitors are based primarily on PK
parameters, whereas in this study, we provide both PK and PD
data in support of E7449 twice-daily dosing.
In preclinical studies, E7449 at a dose of 100 mg/kg, resulted
in sustained PARP inhibition in tumours, similar to published
reports for olaparib and niraparib.17,31,32 In addition to inhibition
of PARP1/PARP2, E7449 is a robust inhibitor of the telomere-
associated PARP enzymes tankyrase 1/2.17 While no PD
assessments of the tankyrase-inhibitory activity of E7449 were
clinically available at the time of this trial, preclinical studies
indicate that E7449 inhibits tankyrase 1/2 with IC50 values from
50 to 120 nmol/L.17 In contrast, the IC50 values for tankyrase
inhibition by olaparib, niraparib and veliparib are 5–20-fold
higher.17 Therefore, the greater inhibition of tankyrase 1/2 by
E7449 differentiates it from other PARP inhibitors, and might
lead to distinct clinical opportunities for this agent. In particular,
patients with tumours showing aberrant activation of the Wnt/β-
catenin pathways (e.g., colorectal and lung cancer) may benefit
from tankyrase-targeted therapy.33,34
Inhibition of DNA repair with PARP inhibitors is an effective
cytotoxic strategy when used in patients with tumours that are
deficient in BRCA1 and BRCA2.27 In this study, 50% (3/6) of patients
with BRCA mutations showed a response of either partial response
(n= 1, high-grade serous ovarian tumour) or stable disease (n= 2,
pancreatic tumour and high-grade serous ovarian tumour),
highlighting the preliminary activity of E7449 in patients with
BRCA mutations. As PARP inhibition has proven to be a highly
effective therapeutic approach in the treatment of ovarian cancers
that have an underlying defect in DNA repair mechanisms,
conducting randomised, phase 2 trials to evaluate the efficacy of
E7449 in tumours with mutations in DNA repair genes may be
useful.
Since PARP1 is known to influence both tumour vasculature and
gene transcription in immune cells,35,36 exploratory assessment of
serum immune-related and angiogenesis biomarker concentrations
over time was assessed. A significant increase from baseline in sIL-
2Rα in patients receiving E7449 was observed. It has been suggested
that sIL-2Rα levels may serve as a marker of regulatory T-cell (Treg)
number and/or function.37,38 Interestingly, it has been shown that
PARP1 regulates Treg function via FOXp3 signalling.39,40 Experiments
in preclinical models demonstrate that direct inhibition of both
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PARP1 and PARP1-knockout mice shows increases in the numbers of
Tregs in the periphery.41,42 Although our biomarker observations of
increased serum sIL-2Rα with E7449 dosing only represent a
surrogate of potential Treg activity, the results are consistent with
preclinical observations. While additional studies examining the
effects of PARP inhibitors on Treg populations are still needed, these
preliminary data suggest that investigation into a combination
approach using a PARP inhibitor and a Treg-targeting agent should
be considered.
The 2X-121 DRP is a step towards realising the promise of
personalised medicine—by using patients’ tumour gene-
expression profiles, it successfully predicted response to treatment
with the PARP inhibitor, E7449. The 2X-121 DRP successfully
combined microarray and drug-sensitivity data from cell lines to
predict the response. While the number of samples used for
testing the novel 2X-121 DRP biomarker is very limited, this drug-
specific biomarker approach has previously been applied to other
chemotherapies, and has demonstrated its predictive value.21,22
Moreover, additional studies, including two ongoing phase 2
clinical trials (NCT03878849 and NCT03562832), wherein the 2X-
121 DRP biomarker will be employed prospectively, will be used to
further validate these results.
In conclusion, the safety, tolerability and preliminary efficacy of
once-daily E7449 600 mg in patients with advanced solid tumours
seems promising, encouraging further clinical evaluation of this
drug. To this end, two phase 2 clinical trials investigating the
efficacy of E7449 (aka, 2X-121) in patients selected by the 2X-121
DRP are currently recruiting patients (NCT03878849, advanced
ovarian cancer; NCT03562832, metastatic breast cancer).
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